2025年4月22日 星期二
首页        期刊介绍        编委会        投稿指南        期刊订阅        广告合作        联系我们        English
河北医学  2022, Vol. 28 Issue (3): 472-477    DOI: 10.3969/j.issn.1006-6233.2022.03.025
  临床研究 本期目录 | 过刊浏览 | 高级检索 |
奥美拉唑联合肠道微生态调节剂治疗新生儿坏死性小肠结肠炎的疗效分析
杨雪, 赵旭晶
山西省运城市中心医院新生儿科, 山西 运城 044000
An Analysis of the Efficacy of Omeprazole Combined with Intestinal Microecological Regulator in the Treatment of Neonatal Necrotizing Enterocolitis
YANG Xue, ZHAO Xujing
Yuncheng Central Hospital, Shanxi Yuncheng 044000, China
全文: PDF (1247 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 目的:分析奥美拉唑联合肠道微生态调节剂对新生儿坏死性小肠结肠炎(NEC)的治疗效果。方法:选取2016年1月至2021年7月到我院就诊的NEC患儿为研究对象,根据非随机临床同期对照及家属自愿原则分为观察组和对照组。给予对照组患儿肠道微生态调节剂治疗,观察组在对照组的基础上采用奥美拉唑联合治疗。比较两组患儿临床症状缓解时间及治疗3d后的临床疗效;比较两组治疗前及治疗后的肠道菌群情况、免疫功能及影像学表现。结果:观察组患儿治疗期间的腹泻、腹胀及大便异常缓解时间低于对照组,其治疗3d后的临床疗效优于对照组(P均<0.05);两组治疗3d后的肠道菌数量(肠道细菌总数、球菌总数、杆菌总数)、CD4+比例及CD4+/CD8+比值较治疗前升高,且观察组治疗前后的差值大于对照组(P均<0.05);两组治疗3d后的血清CRP、PCT水平低于治疗前,且观察组治疗前后的差值与对照组比较差异有统计学意义(P均<0.05);观察组治疗前后的肠壁增厚、固定肠袢影改善比例显著高于对照组(P均<0.05),而两组治疗前后门静脉积气改善比例比较差异无统计学意义(P>0.05)。结论:奥美拉唑联合肠道微生态调节剂治疗可有效提高NEC患儿免疫力,缓解炎症反应,缩短病程,促进康复。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
杨雪
赵旭晶
关键词 新生儿坏死性小肠结肠炎奥美拉唑肠道微生态调节剂影像学特征征象免疫功能    
AbstractObjective: To analyze the therapeutic effect of omeprazole combined with intestinal microecological regulator on neonatal necrotizing enterocolitis (NEC). Methods: Children with NEC who came to the hospital for treatment between January 2016 and July 2021 were selected as the research subjects, and they were divided into observation group and control group according to the principles of non-randomized clinical concurrent control and voluntariness of family members. The children in the control group were treated with intestinal microecological regulator, and the children in the observation group were given omeprazole on the basis of the control group. The relief time of clinical symptoms and clinical efficacy after 3d of treatment were compared between the two groups of children. The intestinal flora, immune function and imaging manifestations of the two groups were compared before and after treatment. Results: The diarrhea relief time, abdominal distension relief time and relief time of irregular bowel movement during treatment of observation group were shorter than those of control group, and the clinical efficacy after 3 d of treatment was better than that of control group (all P<0.05). The intestinal flora counts (total number of intestinal bacteria, total number of cocci, total number of bacilli), proportion of CD4+ and CD4+/CD8+ ratio after 3 d of treatment in the two groups were increased compared with those before treatment, and the differences before and after treatment were greater in observation group than those in control group (all P<0.05). The levels of serum CRP and PCT in the two groups were lower after 3d of treatment than those before treatment, and the differences before and after treatment between observation group and control group were significant (all P<0.05). The improvement ratios of intestinal wall thickening and fixed intestinal loop shadow before and after treatment in observation group were higher than those in control group (all P<0.05), but there was no statistical significance in the improvement ratio of portal venous gas between the two groups before and after treatment (P>0.05). Conclusion: Omeprazole combined with intestinal microecological regulator can effectively improve the immunity, relieve the inflammatory response, shorten the course of disease, and promote the rehabilitation of children with NEC.
Key wordsNeonatal necrotizing enterocolitis    Omeprazole    Intestinal microecological regulator    Imaging characteristic signs    Immune function
    
基金资助:国家卫生健康委医药卫生科技课题,(编号:WA2020HK49)
通讯作者: 赵旭晶   
引用本文:   
杨雪, 赵旭晶. 奥美拉唑联合肠道微生态调节剂治疗新生儿坏死性小肠结肠炎的疗效分析[J]. 河北医学, 2022, 28(3): 472-477.
YANG Xue, ZHAO Xujing. An Analysis of the Efficacy of Omeprazole Combined with Intestinal Microecological Regulator in the Treatment of Neonatal Necrotizing Enterocolitis. HeBei Med, 2022, 28(3): 472-477.
链接本文:  
http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2022.03.025     或     http://www.hbyxzzs.cn/CN/Y2022/V28/I3/472
冀ICP备2025106803号    冀公网安备13080202000786号
版权所有 © 2016 《河北医学》杂志社
本系统由北京玛格泰克科技发展有限公司设计开发